Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of...( Confirms commitment to accelerating ...)

Confirms commitment to accelerating market penetration and revenue growth

SCOTTSDALE, Ariz., May 1 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today that Scott Robey joined the company as Vice President of Marketing. Most recently Mr. Robey served as Senior Director of Marketing at Kinetic Concepts, Inc (KCI) for the V.A.C.(R) Therapy brand, during the time US product sales grew from approximately $70 million in 2000 to almost $1.0 billion in 2007.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Scott is a proven leader with a record of successfully developing and executing significant growth strategies. His responsibilities include accelerating market penetration of the Provant Wound Therapy System, and expanding our platform technology into adjacent markets," said Virginia Rybski, Acting President of Regenesis. "Scott complements our senior management team, which has experience in early stage, rapidly developing companies, and management of mid-to-large medical technology organizations."

Mr. Robey is an 18 year marketing veteran. He held marketing positions at KCI, Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc). His responsibilities have included product management, new product development and commercialization, branding, clinical education programs, and key opinion leader and society relationship development. Mr. Robey has an M.S. in Management from Purdue University, and a B.S. in Biomedical Engineering from Louisiana Tech University.

About the Provant Wound Therapy System

Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causin
'/>"/>